小细胞肺癌从非小细胞肺癌转变:生物机制和临床相关性
1Department of Pathology, The Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, China.
Chinese medical journal pulmonary and critical care medicine
|August 22, 2024
概括
在治疗期间,非小细胞肺癌 (NSCLC) 可以转化为小细胞肺癌 (SCLC),从而导致治疗耐药性. 本综述探讨了这种转变的机制,临床影响和治疗策略,帮助未来的研究.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 翻译研究是翻译研究.
背景情况:
- 肺癌是一个主要的全球健康问题,主要有两种类型:NSCLC和SCLC.
- 在治疗期间,从NSCLC转变为SCLC的组织学转变可能会发生,通常会对治疗产生抗性.
- 了解这种转变对于改善患者治疗结果至关重要.
研究的目的:
- 综合审查SCLC从NSCLC转变的现象.
- 分析推动这种转变的潜在生物机制.
- 讨论转化后的临床相关性和潜在的治疗策略.
主要方法:
- 对NSCLC转化为SCLC的研究进行系统文献综述.
- 分析涉及组织学变化的生物途径.
- 对临床数据关于治疗耐药性和结果的评估.
主要成果:
- NSCLC转化为SCLC与针对性疗法,免疫疗法和化疗的获得性耐药性有关.
- 正在阐明驱动这种转变的特定分子机制.
- 这种转变会影响患者的预后和治疗选择.
结论:
- 从NSCLC转变为SCLC是一个重大的临床挑战.
- 对转变瘤的机制和有效治疗方法的进一步研究是有必要的.
- 更深入的理解可能会导致对抗性肺癌的新型治疗方法.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.5K
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
16.9K
相关概念视频
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Cancers Originate from Somatic Mutations in a Single Cell
11.8K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
11.8K
Tumor Progression
6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
